Febuxostat (Uloric) for Chronic Treatment of Gout
Febuxostat (Uloric - Takeda), a xanthine oxidase inhibitor, has been approved by the FDA for chronic management of hyperuricemia in patients with gout. It is the first drug marketed for treatment of gout in 40 years. Febuxostat is structurally unrelated to allopurinol, the only other commercially available inhibitor of xanthine oxidase. Xanthine oxidase inhibitors decrease serum urate concentrations by decreasing urate synthesis....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Febuxostat (Uloric) for Chronic Treatment of Gout
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1312
Article Code: 1312a
Date: May 18, 2009
Volume: 51
Pages: 37-38
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1312
Article Code: 1312a
Date: May 18, 2009
Volume: 51
Pages: 37-38
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)